Trevor M. Jones

Prof. Trevor M Jones, CBE (Pharmaceutical and biotech industry) Professor Trevor M Jones, former Head of R&D, at Wellcome FRSC, FRSM, FPS, Hon FRCP, FBPharmacolS, FFPM, FCPP, BPharm (Hons), PhD (London), CChem, Hon PhD (Athens), Hon DSc (Strathclyde), Hon DSc (Nottingham) , Hon DSc (Bath) , Hon DSc (Bradford) was born on 19 August 1942. He continues to have a distinguished career in the pharmaceutical and biotech industry as well as in academia.

As main Board Director9 for Research & Development at The Wellcome Foundation Ltd (Wellcome plc) he was responsible for the successful development of a number of significant new products.

Professor Jones assisted the Government to attract inward investment into the UK, particularly from the Japanese Pharma companies through the "Prescribe UK" initiative (with Virginia Bottomley and David Sainsbury).

He was not only involved in the introduction of AZT at his time with the Wellcome Foundation9 but also its pricing in the USA/EU and liaison with the South African Government over patents.

Prof. Jones also led negotiations with the UK Government on the Pharmaceutical Price Regulation Scheme (PPRS) when he was head of the ABPI. His latest role is with Growing Life Sciences in Wales (WAG Fund administered by Arthurian Life Sciences Ltd).

Education

Wolverhampton Grammar School (1953-1955) Professor Jones attained his PhD in Medicine at the King’s College London, University of London This was followed by a Post Doctoral fellowship.

Career

Early career: From 1972 until 1975, Prof. Jones was Head of Development at The Boots Co Ltd. During his time there he was responsible for the technical development of several new products, notably Prothiaden (antidepressant) and Froben (anti-inflammatory), a range of generic products and the technology transfer of Brufen/Nurofen (anti-inflammatory) to many overseas units, notably Upjohn, USA.

Prof. Jones worked for the Wellcome Foundation Ltd from 1974 to 1994 and, as R&D Director was responsible for over 2,500 staff covering all scientific, technical and medical specialities as well as Quality Assurance and Patents/Agreements .

As a member of the Board of Wellcome plc1 from 1987 to 1994, he was intimately involved in the offering of shares by The Wellcome Trust. Prof. Jones was responsible for the disposal of Wellcome's interests in vaccines to Medeva (Evans) and the subsequent re-integration of all aspects of biotechnology into the mainstream business. This included a term as the Director responsible for the biotech joint-venture Wellgen in the USA involving the buy-out of the partner (Genetics Institute) share.

During his time as R&D Director, Prof. Jones was responsible for the successful development of Zovirax (anti-herpes); Lamictal (anti-epileptic); Retrovir: AZT (anti-HIVAIDS) ; Acrivastine (anti-histamine); Atovaquone (PCP/Malaria); Exosurf (infant respiratory distress); Mivacron and Nuromax (neuromuscular blockade); Wellferon (Hepatitis B&C); Zolmitriptan (anti migraine); plus an extensive range of over-the-counter formulations; particularly products for coughs and colds, analgesia and skin care. He also led initiatives concerned with licensing-in of new product opportunities including Centocor (Panorex), Fujisawa USA (LNMMA), Laboratoires Pierre Fabre (Navelbine).

Prior to his appointment to the Board of Wellcome plc, Prof. Jones was Director of Development and established a new Pesticides R&D operation which was included in the sale of the Wellcome hygiene business to Rhône-Poulenc.

From 1994 until August 2004, Prof. Jones was Director General of the Association of the British Pharmaceutical Industry (ABPI) where he directed all the industry activities: government relations on behalf of the 100 national and international pharmaceutical companies. In that capacity, Prof. Jones was a member of the UK Government, on the Pharmaceutical Industry Ministerial Strategy Working Group on Pharmaceuticals, on the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA).

For 12 years Prof. Jones was a member of the UK Government Regulatory Agency, The Medicines Commission; an advisor to the Cabinet Office on the Human Genome Project in 2001; a member of the Prime Minister’s Task force on the Competitiveness of the Pharmaceutical Industry (PICTF) and Chair of the Government Advisory Group on Genetics Research.

He has held his current position since 2004 as a Director of Allergan Inc. at Irvine CA (USA) , been a member of the Board of Directors of VeronaPharma plcsince 2007, this being a spin-out company developing drugs for COPD, coughs and asthma. The International Clinical Research Organisation, Synexus Ltd and Chairman of the CRO Simbec Research Ltd and a Trustee of The UK Stem Cell Foundation .

He has served on a number of other Boards as Director in the UK: NextPharma Ltd since 2005 (contract manufacturer), ReNeuron plc from 1998 to 2012 (stem cell therapy), in the Netherlands: BAC BV (bioaffinity company), in Italy from 2004 to 2008: Sigma-Tau Finanziaria S.p.A (Pharmaceuticals) , in the USA: SciClone Inc (Biotech) and President of Sigma-Tau Pharmaceuticals Inc (Rare Diseases) from 2010 to 2011.

From 2000 until 2008, he was Vice Chair of King’s College London Council . He holds honorary degrees/fellowships/gold medals from seven universities, was awarded an Honorary Fellowship of the Royal College of Physicians and The British Pharmacological Society and was elected to the French Academie Nationale de Pharmacie .

He has published more than 150 papers in learned and professional journals and is on the editorial board of a number of journals.

He is a frequent guest lecturer at international pharmaceutical conferences and seminars and has appeared regularly on radio and TV on pharmaceutical and medical issues.

During the period 2003-2005, Prof. Jones was a Commissioner at the World Health Organization (WHO) on the Commission for Intellectual Property, Innovation and Public Health (CIPIH) .

He was a founder member and a member of the Board of the Medicines for Malaria Venture MMV

Prof. Jones advises the Government of the Netherlands on Life Science as a member of the TiPharma Advisory Board . He is also a member of the EU Commission IMI Scientific Advisory Board.

In 2005 he was the winner of the SCRIP Life Time Achievement award for his contribution to pharmaceutical sciences and the industry .

In 2003 Her_Majesty_Queen_Elizabeth_II conferred on him the honour of Commander of the Most Excellent Order of the British Empire (CBE)

Honours and distinctions

Professor Jones has a wealth of honours and distinctions. In 1987 he was awarded a fellowship of the Royal Pharmaceutical Society of Great Britain. Other honours and distinctions, which have been awarded are:

• 1987: Harrison Memorial Medal, Royal Pharmaceutical Society of Gt Britain
• 1992: Gold Medal, Comenius University
• 1993: Hon. [Doctor of Philosophy | PhD]] P, University of Athens
• 1994: Hon. DSc, University of Strathclyde
• 1994: Fellowship, King's College, University of London
• 1995: Hon. Fellowship, Faculty of Pharmaceutical Medicine, Royal College of Physicians
• 1996: Charter Gold Medal, Royal Pharmaceutical Society of Great Britain
• 1998: Hon. Fellowship, The School of Pharmacy, University of London
• 1998: Hon. DSc, University of Nottingham
• 1999: PHARMA Outstanding Achievement Award
• 1999: FIP lifetime award for outstanding contribution to Biotechnology
• 2000: Hon. DSc, University of Bath
• 2003: C.B.E. – HM The Queen’s New Years Honours List
• 2003: Hon DSc, University of Bradford
• 2005: Hon Fellowship, British Pharmacological Society
• 2005: Hon Fellowship, Royal College of Physicians
• 2005: Winner, SCRIP Life Time Achievement Award
• 2005: Elected to Foreign Fellowship of the Academie Nationale de Pharmacie FRANCE
• 2006: Hon. Fellowship, College of Pharmacy Practice
• 2007: Fellow of the Royal Society of Medicine

Committees and Advisory Boards

• 1974-9: Member of the Formulation Panel of the "British Pharmaceutical Codex" BPC
• 1975: Founder member of the steering group of "Drug Excipient Catalogue”
• 1976-82: Member of Expert Committees of the British Pharmacopoeia: (a) Tablet Dissolution Panel: 1976-1982; (b) Committee F - Formulation since 1982
• 1978-83: UK Council for National Academic Awards (CNAA) Pharmacy Research Board
• 1978-83: Member of Industrial Pharmacy Committee, Federation International Pharmaceutique (FIP): (a) Member of FIP expert working group on drug dissolution 1979-1984; (b) President of the FIP International Commission of Technology - 1979-1983; (c) Member of the Board of Pharmaceutical Sciences of FIP - 1980-1984 and 1995-7,1981- Founder Member of the Board of Governors of the College of Pharmacy Practice
• 1982-94: UK Medicines Commission
• 1983: Member of the Medical/Technical Committee of the IFPMA
• 1983: Chairman of the British Pharmaceutical Conference, London
• 1983: Advisor to the Commission of the European Communities (EEC) Committee for the European Development of Science and Technology (CODEST)
• 1983: Association of the British Pharmaceutical Industry (ABPI) Working Groups / Committees - Education in pharmaceutical science, technology and manufacture – R&D Committee (1990-94)
• 1984: Member of the Board of the Science Policy Support Group (SPSG), UK
• 1984: Steering Committee of COPHARM
• 1984: Policy Board, Centre for Medicines Research (CMR) – Chairman of the Innovation Advisory Board 1990-98
• 1991-: President of the Board, Maurice-Marie Janot International Lecture
• 1991: Advisory Board on the Human Genome to the UK Government Cabinet Office
• 1992: Expert Working Party on the Use of Tissues, Nuffield Council on Bioethics
• 1993: Board of Honorary Advisers, The Glynn Research Foundation, 1993
• 1994: Cabinet Office Advisory Board on UK: Israel Research Activities
• 1995: The Epilepsy Research Foundation - Industrial Co-ordinator 1995 - Trustee, The Epilepsy Research Foundation 1996-2001 - Vice President 2001
• 1995: Member of Council, London Medicine
• 1996-8: National Biological Standards Board (NBSB) Review
• 1996: Steering Group of Government Review of Department of Health and Medical Research Council Research Establishment
• 1997: Trustee, Northwick Park Institute of Medical Research
• 1997-8: Trustee, Institute of Aviation Health
• 1997-: Medical Research Council (Appointments Committee and Advisory Board)
• 1997-8: Home Office Review of Forensic Science Service (National Public Laboratory); NHS R&D National Co-Centre for Health Technology: Assessment (NCCHTA) 1998-2000
• 2001: Prime Minister’s Task force on the Competitiveness of the Pharmaceutical Industry (PICTF)
• 2001-: Dept. of Health working group on Genetics Knowledge Parks; DfID High Level Working Group on Medicines for the Developing World; Chair, European Federation of Pharmaceutical Industries and Associations (EFPIA) D&D Directors’ Group Advisory Board, MRC Social, Genetic and Developmental Psychiatry research centre, Institute of Psychiatry
• 2003: Commissioner, World Health Organisation, Commission on Intellectual Property, Innovation and Public Health , Trustee, British Urological Foundation , Member of the advisory board “Sense about Science”
• 2008-: Advisory Board, MRC Centre for Neurodegeneration
• 2010-: Advisory Board, Academy of Pharmaceutical Sciences

Interests

Welsh Rugby, Golf, Gardening

Clubs and Associations

Professor Jones is a member of The Athenaeum, Pall Mall, London; a Liveryman of the Guild of Apothecaries, London; and a Freeman of the City of London.